受脱氧核苷酸钠联合集落刺激因子治疗骨髓抑制meta分析  

Meta-analysis of Bone Marrow Suppression by Deoxynucleotide Sodium Combined with Colony Stimulating Factor

作　　者：张强 ZHANG Qiang(Department of Gastroenterology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing,100053 China)

机构地区：[1]中国中医科学院广安门医院消化内科

出　　处：《系统医学》2019年第23期69-73,79,共6页Systems Medicine

摘　　要：目的系统评价脱氧核苷酸钠治疗骨髓抑制的疗效及安全性。方法计算机检索Cochrane图书馆、PubMed、EMbase、CBM、CNKI、维普数据库和万方数据库,手工检索相关杂志、会议论文和学位论文,收集脱氧核苷酸钠联合集落刺激因子治疗骨髓抑制的随机对照试验(RCTs)。由两名研究者独立选择试验、评价质量、提取数据,并交叉核对。使用RevMan 5.3软件进行meta分析。结果RCT共纳入8项:①预防及治疗白细胞减少和血小板减少;②提高免疫细胞数量(CD3细胞、CD4细胞、NK细胞);③降低骨髓总体抑制率及Ⅲ、Ⅳ度抑制率;④减少化疗所致肝损害等方面;治疗组疗效均优于对照组,组间相比差异有统计学意义(P=0.025)。结论脱氧核苷酸钠用于改善骨髓抑制安全有效,但尚待大样本、高质量、多中心随机双盲对照研究证实。Objective To systematically evaluate the efficacy and safety of sodium deoxynucleotide in the treatment of myelosuppression.Methods Computer search for Cochrane Library,PubMed,EMbase,CBM,CNKI,VIP database and Wanfang database,manually search related journals,conference papers and dissertations,and collect randomized controlled trials of sodium deoxynucleotide combined with colony stimulating factor in the treatment of myelosuppression(RCTs).Two investigators independently selected trials,assessed quality,extracted data,and cross-checked.Meta analysis was performed using RevMan 5.3 software.Results A total of 8 RCTs were included:1.prevention and treatment of leukopenia and thrombocytopenia;2.increasing the number of immune cells(CD3 cells,CD4 cells,NK cells);3.reducing the overall inhibition rate of bone marrow and III,IV inhibition rate,and 4.reducing the liver damage caused by chemotherapy;the treatment group was better than the control group,the difference between the groups was statistically significant(P=0.025).Conclusion Deoxynucleotide sodium is safe and effective for improving myelosuppression,but it has yet to be confirmed by large sample,high quality,multicenter randomized double-blind controlled study.

关 键 词：脱氧核苷酸钠 集落刺激因子 骨髓抑制 白细胞 血小板 疗效 安全性 

分 类 号：R4[医药卫生—临床医学]